Loading...
Market
Will Anvisa revoke approval of Lirux or Olire by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Anvisa
Story
Anvisa Approves EMS Production of Liraglutide Medications Lirux and Olire, First Competitor to Ozempic, for Sale in 2025
Dec 24, 2024, 02:11 PM
The Brazilian Health Regulatory Agency (Anvisa) has approved the production of two liraglutide-based medications by the pharmaceutical company EMS. The drugs, named Lirux and Olire, are intended for the treatment of type 2 diabetes and obesity, respectively. This marks the introduction of the first national competitor to Ozempic, a medication widely used for similar purposes. The approval was officially published in the Diário Oficial on December 23, 2024, and the medications are expected to be available for commercial sale in 2025. In a separate development, Anvisa has prohibited a supplement that falsely claimed to cure diabetes, which had been linked to misleading information about the disease.
View original story
Similar markets
Rejected • 33%
Pending • 34%
Approved • 33%
EMA only • 25%
FDA only • 25%
Both FDA and EMA • 25%
Neither • 25%
No • 50%
Yes • 50%
Withdrawn • 25%
Approved • 25%
Pending • 25%
Rejected • 25%